Rituximab and Hyaluronidase Human

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
(rih-TUK-sih-mab … HY-al-yoo-RAH-nih-days)

This page contains brief information about rituximab and hyaluronidase human and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Rituxan Hycela
FDA Approved

FDA Approval for Rituximab and Hyaluronidase Human

Use in Cancer

Rituximab and hyaluronidase human is approved to be used alone or with other drugs to treat:

Rituximab and hyaluronidase human is a form of rituximab that is given as a subcutaneous injection. This form can be given more quickly than rituximab, which is given as an infusion. This shortens the amount of time it takes to receive each treatment. The subcutaneous form is used only after patients have received one full dose of rituximab by infusion. For more information about rituximab that may apply to rituximab and hyaluronidase human, see the Drug Information Summary for Rituximab.

More About Rituximab and Hyaluronidase Human

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Targeted Cancer Therapies

Biological Therapies for Cancer

New Rituximab Formulation Approved for Some Lymphomas, Leukemia

Clinical Trials Accepting Patients

Find Clinical Trials for Rituximab And Hyaluronidase Human - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted: September 1, 2017